C12N 2770/24164
By serial passage
Official title: by serial passage
C12N2770/24164 (By serial passage) appears on 27 US grants and 30 published applications in this corpus.
Search patents in C12N- Granted patents
- 27
- Published applications
- 30
- Assignees
- 15
- Inventors
- 75
- Latest grant
- 8 Oct 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 4 | 0 |
| 2004 | 1 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 1 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 2 | 2 |
| 2011 | 2 | 0 |
| 2012 | 0 | 3 |
| 2013 | 1 | 0 |
| 2014 | 1 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 2 |
| 2020 | 1 | 1 |
| 2021 | 1 | 6 |
| 2022 | 4 | 2 |
| 2023 | 2 | 2 |
| 2024 | 3 | 1 |
| 2025 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Zika vaccines and immunogenic compositions, and methods of using the same8 Oct 2024US 12,109,260 B2Takeda Vaccines, Inc.
- Method for inactivating zika virus and for determining the completeness of inactivation23 Apr 2024US 11,964,008 B2Takeda Vaccines, Inc.
- Rapid method of generating live attenuated vaccines9 Jan 2024US 11,865,083 B2National University of Singapore
- Zika vaccines and immunogenic compositions, and methods of using the same22 Aug 2023US 11,730,802 B2Takeda Vaccines, Inc.
- Zika vaccines and immunogenic compositions, and methods of using the same16 May 2023US 11,648,304 B2Takeda Vaccines, Inc.
- Chimeric zika virus anticancer vaccine obtained through breast cancer cell passage25 Sep 2025US 2025/0295750 A1
- Compositions and methods of vaccination against dengue virus in children and young adults24 Jul 2025US 2025/0235522 A1Takeda Vaccines, Inc.
- Method for inactivating zika virus and for determining the completeness of inactivation3 Oct 2024US 2024/0325518 A1Takeda Vaccines, Inc.
- Zika vaccines and immunogenic compositions, and methods of using the same28 Dec 2023US 2023/0414743 A1Takeda Vaccines, Inc.
- Method for inactivating zika virus and for determining the completeness of inactivation11 May 2023US 2023/0145065 A1Takeda Vaccines, Inc.
Most cited
By later US patents
- Dengue serotype 2 attenuated strain10US 7,641,908 B2Center for Disease Control and Prevention · 2010
- Multivalent dengue virus vaccine8US 7,217,418 B2The United States of America as represented by the Secretary of the Army · 2007
- Dengue serotype 1 attenuated strain8US 7,641,907 B2Center for Disease Control and Prevention · 2010
- Multivalent dengue virus vaccine5US 6,638,514 B1The United States of America as represented by the Secretary of the Army · 2003
- Dengue serotype 1 attenuated strain4US 8,067,565 B2Centers for Disease Control and Prevention · 2011